Literature DB >> 33243730

[Effect of small interfering RNA-mediated BIRC6 silencing on apoptosis and autophagy of renal cancer 786-O cells].

Kaihua Zhong1, Dong Chen2, Zhiming Wu2, Xiaohong Wang3, Bin Pan4, Nanhui Chen1, Weifeng Zhong1,2.   

Abstract

OBJECTIVE: To study the expression of BIRC6 in renal cancer tissues and investigate the effect of BIRC6 silencing on apoptosis and autophagy of 786-O cells.
METHODS: Twenty surgical specimens of renal cancer tissues and adjacent renal tissues were collected from Meizhou People's Hospital between February, 2016 and December, 2018 for detection of BIRC6 protein expression using immunohistochemistry. Renal cancer 786-O cells were transfected with a control small interfering RNA (siRNA) or BIRC6 siRNA via lipofectamine 2000, and the changes in cell proliferation and apoptosis following 5-FU treatment were assessed using CCK8 assay and flow cytometry; the expressions of autophagy-related proteins Beclin and LC3A/B were detected by Western blotting.
RESULTS: The expression of BIRC6 protein was significantly higher in renal cancer tissues than in the adjacent renal tissues. Western blotting showed that siRNA-mediated silencing of BIRC6 significantly lowered the expression of BIRC6 in 786-O cells. In the cells with BIRC6 silencing, treatment with 12.5, 25, 50, 100 and 200 μg/mL 5-FU resulted in significantly higher proliferation inhibition rates than in the cells transfected with the control siRNA (P < 0.01). BIRC6 silencing also significantly increased the apoptosis rate of 786-O cells following 5-FU treatment (P < 0.01). The results of Western blotting showed that BIRC6 silencing significantly lowered the protein expressions of Beclin and LC3A/B in 786-O cells.
CONCLUSIONS: Interference of BIRC6 mediated by siRNA can inhibit autophagy and promote 5-FU-induced apoptosis to enhance the sensitivity of 786-O cells to 5-FU.

Entities:  

Keywords:  BIRC6; autophagy; drug resistance; renal cancer

Mesh:

Substances:

Year:  2020        PMID: 33243730      PMCID: PMC7704388          DOI: 10.12122/j.issn.1673-4254.2020.11.18

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  32 in total

1.  LncRNA SNHG5 promotes cisplatin resistance in gastric cancer via inhibiting cell apoptosis.

Authors:  M Li; Y-Y Zhang; J Shang; Y-D Xu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-05       Impact factor: 3.507

2.  Mass Spectrometry Imaging Enables Discrimination of Renal Oncocytoma from Renal Cell Cancer Subtypes and Normal Kidney Tissues.

Authors:  Jialing Zhang; Shirley Q Li; John Q Lin; Wendong Yu; Livia S Eberlin
Journal:  Cancer Res       Date:  2019-12-16       Impact factor: 12.701

3.  The correlation between autophagy and tamoxifen resistance in breast cancer.

Authors:  Junxia Liu; Wei Yue; Haiyan Chen
Journal:  Int J Clin Exp Pathol       Date:  2019-06-01

4.  The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.

Authors:  Chunmin Ge; Chrystelle L Vilfranc; Lixiao Che; Raj K Pandita; Shashank Hambarde; Paul R Andreassen; Liang Niu; Olugbenga Olowokure; Shimul Shah; Susan E Waltz; Lee Zou; Jiang Wang; Tej K Pandita; Chunying Du
Journal:  Hepatology       Date:  2019-03-13       Impact factor: 17.425

5.  Depletion of BIRC6 leads to retarded bovine early embryonic development and blastocyst formation in vitro.

Authors:  Dessie Salilew-Wondim; Micheal Hölker; Franca Rings; Chirawath Phatsara; Abdollah Mohammadi-Sangcheshmeh; Ernst Tholen; Karl Schellander; Dawit Tesfaye
Journal:  Reprod Fertil Dev       Date:  2010       Impact factor: 2.311

6.  BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis.

Authors:  Eman Abdel Rahman Ismail; Hanan Mohamed Mahmoud; Lamis Mohamed Tawfik; Deena Mohamed Habashy; Amira Abdel Moneam Adly; Nayera Hazaa El-Sherif; Mahmoud Ahmed Abdelwahab
Journal:  Eur J Haematol       Date:  2012-01-04       Impact factor: 2.997

7.  MiR-181a Promotes Apoptosis and Reduces Cisplatin Resistance by Inhibiting Osteopontin in Cervical Cancer Cells.

Authors:  Xiaofei Xu; Xiaofei Jiang; Liping Chen; Yu Zhao; Zhihua Huang; Huifang Zhou; Mingqing Shi
Journal:  Cancer Biother Radiopharm       Date:  2019-08-22       Impact factor: 3.099

8.  BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.

Authors:  Wenqing Tang; Ruyi Xue; Shuqiang Weng; Jian Wu; Ying Fang; Yi Wang; Lingling Ji; Tingting Hu; Taotao Liu; Xiaowu Huang; She Chen; Xizhong Shen; Si Zhang; Ling Dong
Journal:  Int J Cancer       Date:  2014-09-18       Impact factor: 7.396

9.  Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.

Authors:  Irina Proskorovsky; Agnes Benedict; Sylvie Negrier; Danielle Bargo; Rickard Sandin; Krishnan Ramaswamy; Jigar Desai; Joseph C Cappelleri; James Larkin
Journal:  BMC Cancer       Date:  2018-12-19       Impact factor: 4.430

10.  Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer.

Authors:  Tsutomu Anraku; Hiroo Kuroki; Akira Kazama; Vladimir Bilim; Masaaki Tasaki; Daniel Schmitt; Andrew Mazar; Francis J Giles; Andrey Ugolkov; Yoshihiko Tomita
Journal:  Int J Mol Med       Date:  2019-12-12       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.